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The seminal discovery of the R403Q mutation in the
beta-myosin heavy chain (MyHC) gene as a cause of
hypertrophic cardiomyopathy (HCM) by Dr. Thierfelder’s
group a decade ago (1) ushered in a new era in the molecular
genetics of HCM. To date, over 120 mutations in 10 genes,
all encoding sarcomeric proteins, have been identified in
patients with HCM (2), leading to the notion that HCM is
a disease of contractile sarcomeric proteins (3). Mutations in
nonsarcomeric genes, mitochondrial genome and genes
responsible for the triplet repeat syndromes also have been
found in patients with HCM (2). Although no large-scale
systematic search has yet been performed, the existing data
suggest that mutations in the beta-MyHC, myosin binding
protein-C (MyBP-C) and cardiac troponin T (cTnT) are
the most common causes of HCM, collectively accounting
for approximately 60% to 70% of all HCM cases (2). It has
also become evident that the frequency of each particular
causal mutation in the HCM population is relatively low
(,5%). Overall, genetic studies indicate significant allelic
and nonallelic heterogeneity of HCM, an issue that com-
plicates the feasibility of genetic diagnosis.
See pages 315 and 322
Identification of the causal mutations for HCM has
afforded the opportunity to identify the genetic determi-
nants of cardiac phenotypes, which are also known to be
extremely variable. The results of several genotype-
phenotype correlation studies suggest that mutations affect
the phenotypic expression of HCM, particularly the mag-
nitude of cardiac hypertrophy and the risk of sudden cardiac
death (SCD). In general, HCM caused by mutations in the
beta-MyHC appears at a younger age and is associated with
more extensive hypertrophy and a higher incidence of SCD
compared to HCM arising from mutations in the MyBP-C
(4–7). The prognostic significance of the causal mutations is
related to their influence on the magnitude of hypertrophy
(8), perhaps with the exception of mutations in the cTnT,
which often are associated with mild left ventricular hyper-
trophy but a relatively high incidence of SCD (9). However,
the results of genotype-phenotype correlation studies in
HCM have been confounded by the small size of the
families, low frequency of each causal mutation, small
number of families with identical mutations, variability of
the phenotypic expression in affected individuals within the
same family or among families with identical mutations and
the effects of modifier genes and environmental factors.
Thus, despite the initial enthusiasm regarding the clinical
utility of the causal mutations as a means of identifying high
risk subjects with HCM, it is evident that no particular
clinical phenotype is mutation-specific. All in all, mutations
exhibit highly variable clinical, electrocardiographic and
echocardiographic manifestations.
In this issue of the Journal, Erdmann et al. (10) report on
the frequency of mutations in the MyBP-C and the asso-
ciated phenotypes in 110 genetically independent patients
with HCM. They identified 13, including 11 novel muta-
tions, in 15 index cases (14%). The spectrum of mutations
included missense, nonsense, splice junction and small
deletion/insertion mutations. Consistent with previous re-
ports (5,6), left ventricular hypertrophy was relatively mild
and the clinical features were diverse. Premature SCD,
myomectomy to relieve outflow tract gradients, and implan-
tation of defibrillator for sustained ventricular arrhythmias
were also observed and were more common in those patients
with the deletion or truncation mutations. The findings of
Erdmann et al. (10) further illustrate the genetic and clinical
heterogeneity of HCM caused by mutations in MyBP-C.
The frequency of the observed MyBP-C mutations is
subject to the sensitivity of the screening technique, com-
prehensiveness of the screening procedure and selection of
the population. Erdmann et al. (10) used single stranded
conformational polymorphism (SSCP) as the screening
technique, which has a sensitivity of approximately 70% to
80%. In addition, restriction of screening to the coding and
adjacent sequences, although justified and a common prac-
tice, would not allow for detection of mutations that are
located in the regulatory sequences.
Characteristics of the study population are perhaps the
most important determinants of the results of mutational
screening studies. An important feature of HCM and other
autosomal dominant diseases is the age-dependent pen-
etrance of the causal mutations, which is also documented
for the MyBP-C mutations in another study in this issue of
the Journal (11). Screening of the index cases with estab-
lished clinical phenotypes in early life will lead to underes-
timation of the frequency of the mutations that are associ-
ated with a low penetrance. In contrast, screening of elderly
subjects with established phenotypes could lead to underes-
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timation of the true prevalence of mutations that confer a
survival disadvantage, and thus, those associated with a
benign prognosis will be over-represented. The relatively
young age of the 110 index cases in the present study along
with the use of SSCP for mutation detection are likely to
lead to underestimation of the true prevalence of MyBP-C
mutations in the general population of HCM. Determina-
tion of the true prevalence of each particular causal gene and
mutation for HCM requires large-scale epidemiologic stud-
ies in the general population without considering the
presence or absence of the clinical phenotype. Collectively,
based on the previous data (5,6) and the report by Erdmann
et al. (10) it is reasonable to estimate that mutations in the
MyBP-C account for approximately 20% to 25% of all
HCM cases.
Over 40 different mutations in the MYBPC3 gene, which
codes for the MyBP-C protein, have been identified in
patients with HCM. As is the case for mutations in other
causal genes for HCM, no particular MyBP-C mutation
predominates, and the frequency of each mutation is low.
The existing data suggest that the vast majority of the
mutations in HCM arise independently. Thus, a founder
effect (common ancestor) is unusual. An intriguing feature
of mutations in the MYBPC3 gene is their spectrum, which
comprise not only missense mutations but also deletion/
insertion and splice junction mutations (5,7,12). This is
unlike mutations in the beta-MyHC or cTnT, which are
predominantly missense mutations. Deletion/insertion mu-
tations are expected to result in frame-shift or truncation of
the MyBP-C proteins, leading either to severe structural
and functional defects in the protein or to immediate
degradation of the expressed protein. The basis for the
relative preponderance of the frame-shift and truncation
mutations in the MyBP-C protein is unknown, possibly
reflecting the complexity of the gene structure.
Alternatively, one might speculate that mutations,
whether missense or insertion/deletion, occur randomly,
irrespective of the causal genes. However, survival of the
mutation carriers varies according to the functional and
structural significance of the causal gene. Frame-shift or
deletion mutations in the beta-MyHC or cTnT that cause
major structural and functional changes in the protein could
induce an early embryonic death. In contrast, similar mu-
tations in proteins that have lesser roles in sarcomere
structure and function could be compatible with survival
and, thus will be found in patients with HCM.
A characteristic feature of human HCM, like all other
autosomal dominant diseases, is the presence of significant
variability in its phenotypic expression, such as cardiac
hypertrophy and SCD. Factors that account for the vari-
ability of cardiac phenotypes are largely unknown. Diversity
of the causal genes and mutations are partly responsible; but
modifier genes and environmental factors also affect the
phenotypic expression of HCM. Mutations in the MyBP-C
are generally associated with a relatively mild cardiac hyper-
trophy and a low incidence of SCD as compared to
mutations in the beta-MyHC (5,6). However, as shown by
Erdmann et al. (10), malignant features such as SCD,
sustained ventricular tachycardia and severe hypertrophy
also occur. The investigators (10) suggest that severe pheno-
types were more frequent in subjects with the frame-shift
and deletion mutations, which are expected to alter the
structure of the MyBP-C protein drastically. However, the
sample size and the number of events were relatively small
to draw firm conclusions. In addition, this observation is in
contrast to a previous report showing a higher survival rate
in subjects with deletion mutations (5). As stated earlier,
multiple confounding factors limit the overall utility of the
genotype-phenotype correlation studies in HCM, thus em-
phasizing the need for large-scale studies. Hence, compre-
hensive clinical data in conjunction with the genetic infor-
mation should be combined when providing counseling to
subjects with HCM.
Like all other autosomal dominant diseases, penetrance of
the causal mutations in HCM (for clinical phenotypes) is
also age-dependent. Causal mutations, present at birth, do
not lead to hypertrophy and other clinical phenotypes often
until the third and fourth decades of life. Penetrance is
partially mutation-dependent and is relatively low for mu-
tations in the MyBP-C (5,6). Therefore, absence of cardiac
hypertrophy in members of families with HCM in the early
decades of life does not exclude the possibility of develop-
ment of HCM later in life. In this issue of the Journal,
Maron et al. (11) demonstrate this point for mutations in
the MyBP-C by documenting the evolution of cardiac
hypertrophy in subjects who had no hypertrophy on the
initial echocardiograms performed earlier in life. The rela-
tively low sensitivity of echocardiographic findings of car-
diac hypertrophy for early detection of mutation carriers in
HCM is in accord with the current hypothesis that hyper-
trophy is a “compensatory” phenotype secondary to func-
tional and molecular phenotypes (13). Accordingly, a func-
tional phenotype is expected to be more sensitive in
identification of mutation carriers than a structural pheno-
type, such as cardiac hypertrophy. In support of this notion,
we have shown, in a transgenic rabbit model that fully
recapitulates the phenotype of human HCM (14), that
reduced myocardial Doppler velocities identified all muta-
tion carriers even in the absence of cardiac hypertrophy (15).
Thus, we proposed that tissue Doppler imaging, which
detects myocardial contraction and relaxation abnormalities,
could be used for early detection of mutation carriers in
human subjects prior to the development of and indepen-
dent of cardiac hypertrophy.
The basis for the age-dependent penetrance of mutations
responsible for autosomal dominant diseases, such as HCM,
and the reasons for the variations in the penetrance among
subjects with identical mutations or mutation carriers within
a family remain unknown. An attractive hypothesis is the
possible role of mutations in the mitochondrial genome and
reactive oxygen species (ROS). An age-dependent increase
in mitochondrial DNA mutations could lead to an increase
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in the production of ROS, which are known to exert a
diverse array of biologic functions including activation of
hypertrophic signals. Despite the plausibility of the role of
ROS in induction of an age-dependent cardiac hypertrophic
response, their function in modulating cardiac phenotypes
in HCM is speculative.
Genetic factors other than the causal mutations, referred
to as the modifier genes or the genetic background, affect the
phenotypic expression of HCM. Thus, although HCM is a
classic example of a “monogenic” disorder, it is not, in a
sense, purely “monogenic” because expression of multiple
genes affects its phenotype. Causal mutations in the con-
tractile sarcomeric proteins are necessary for the develop-
ment of HCM and contribute significantly to its phenotypic
expression. In contrast, modifier genes that are neither
necessary nor sufficient to cause HCM affect the severity of
cardiac phenotypes. The final phenotype is the product of
the causal mutations, modifier genes and environmental
factors. The identity of the modifier genes for HCM and
the magnitude of their effects have not been systematically
explored. Because of the complexity of the molecular biol-
ogy of cardiac hypertrophy, a large number of genes are
likely to modify expression of cardiac phenotypes in HCM,
each exerting a modest effect. In addition, complex
genotype-genotype and genotype-environment interactions
could influence the phenotypic expression of HCM. It is
estimated that the human genome, comprised of approxi-
mately 30,000 to 50,000 genes, contains 2.1 million single
nucleotide polymorphisms (SNPs). Approximately 100,000
are likely to affect expression levels or structure of the
encoded proteins, and thus exert biologic effects. Based on
the results of simple polymorphism association studies,
several potential modifier genes have been identified includ-
ing the gene encoding angiotensin-1-converting enzyme-1
(16–18). Because of the limitations of association studies
and the allelic and nonallelic heterogeneity of HCM,
large-scale systematic studies are needed to identify the
modifier genes for HCM.
The mechanisms by which mutations in the MyBP-C
protein lead to HCM are largely unknown. The MyBP-C
protein is both a functional and a structural component of
the sarcomere (19). It participates in sarcomere assembly
through binding with other sarcomeric proteins. The last
102 amino acids of MyBP-C bind to the rod and
subfragment-2 regions of MyHC in the A band of the
sarcomere. The MyBP-C protein also binds to titin, a giant
protein that spans the length of the sarcomere at multiple
and regular intervals. Binding of MyBP-C to MyHC and
titin provides stability to sarcomere organization. Also,
MyBP-C modulates cardiac contraction by regulating actin-
activated ATPase activity of the MyHC protein. Cardiac
MyBP-C possesses at least three phosphorylation sites that
are located between amino acids 157 to 259 and are
amenable to phosphorylation by cAMP-dependent- and
calcium/calmodulin-dependent protein kinases (19). Phos-
phorylation of the cardiac-specific domain in response to
adrenergic stimulation modulates cardiac contractility. Mu-
tations in the MyBP-C commonly affect the functional
domains of the MyBP-C, including its binding sites for
MyHC and titin (5,6). The primary defect caused by
mutations in the MyBP-C is likely to be diverse and differ
for missense, frame-shift and truncation mutations. The
MyBP-C proteins carrying the missense mutations could
incorporate into myofibrils but cause myocyte mechanical
dysfunction and impair generation of the contractile force.
Insertion/deletion mutations could lead to expression of
truncated proteins that degrade immediately and cause
haplo-insufficiency, or do not properly incorporate into
sarcomere and cause sarcomere dysgenesis. Thus, mutations
in the MyBP-C could affect orderly formation of thick
filaments and/or alter cardiac myocyte mechanical function,
particularly in response to adrenergic stimulation. Overall,
the expected functional defect conferred by mutations in the
MyBP-C is impaired generation of force of contraction by
the cardiac myocytes, which could lead to increased myocyte
stress and subsequent activation of stress-responsive signal-
ing kinases and increased expression of trophic and mitotic
factors in the heart (13). Activation of signaling kinases and
increased expression of trophic factors lead to activation of
the transcriptional machinery, increased gene expression
and induction of hypertrophy, disarray, fibrosis and other
histologic and clinical phenotypes of HCM.
In conclusion, humans with HCM exhibit a variety of
phenotypes. The variability is due to the diversity of the
causal genes and mutations and effects of the modifier genes
and environmental factors. Large-scale genetic epidemio-
logic studies are necessary to determine the true frequency
of the causal genes and mutations, to identify the modifier
genes and to determine the magnitude of their effects and
the effects of environmental factors on the phenotypic
expression of HCM. Elucidation of the molecular bases for
the diversity of cardiac phenotypes could lead to more
accurate diagnosis, risk stratification and management of
patients with HCM.
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